Furthermore, treatment with increased concentrations of 2-AG did not induce any modification in IL-17A, FoxP3, or IL-4 expression in Th17, Treg, and Th2 lymphocytes, respectively, from both SLE participants and HD (Figure 2). This evidence concerns the gene IL17A and Huntington disease.